Voltage-Gated Calcium Channel (VGCC) Type N Antibodies, Serum

Clinical Utility

Voltage-Gated Calcium Channel (VGCC) Type N Antibody – N-type calcium channel antibodies are more highly associated with primary lung cancer than P/Q-type. One or all of the autoantibodies in the myasthenia gravis (MG)/LEMS evaluation can occur with neoplasia without evidence of neurological impairment. One or both calcium channel antibodies (P/Q and N) can occur with paraneoplastic and idiopathic cerebellar ataxia, encephalomyeloneuropathies, and autonomic neuropathy. Classical symptoms of LEMS include proximal muscle weakness, fatigability, dry mouth and impotence. When presentation is further complicated with oculobulbar weakness, these symptoms can easily be misinterpreted as MG. However, because VGCC antibodies are positive in only approximately 5% of MG patients, the measurement of these antibodies is very useful in distinguishing LEMS from MG.

Method

Radioimmunoassay (RIA)

Result Included

Voltage-Gated Calcium Channel (VGCC) Type N Antibodies

Turnaround Time

14 days

Results

Referral Location

Out-of-Country

Last Updated

2019-11-28